MyHealthChecked PLC Trading update (3575V)
December 13 2021 - 2:00AM
UK Regulatory
TIDMMHC
RNS Number : 3575V
MyHealthChecked PLC
13 December 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
MyHealthChecked plc
( " MyHealthChecked " or " the Company " )
Trading update
Full year results to meet or exceed higher end of expectation
range
MyHealthChecked Plc (AIM: MHC), the consumer home-testing
healthcare company, provides an update on trading for the year
ending 31 December 2021, which is expected to exceed the higher end
range of current market expectations for EBITDA, and meet the
higher end range of current market expectations for turnover.
As announced on 29 September 2021, MyHealthChecked experienced
strong trading in Q3 delivering further revenue growth, a move into
a positive EBITDA position and quarterly cash generation for the
first time.
Despite an anticipated quieter fourth quarter, given that travel
volumes are traditionally lower over that period, high levels of
demand for the recently reinstated PCR Day-2 test kits and
associated laboratory services have resulted in further strong
trading in Q4. The Board is now confident that the full year
revenues will be around GBP16m (FY 2020: GBP49.5k) and deliver an
adjusted EBITDA profit of at least GBP2.1m (FY 2020: GBP2.7m loss).
The business will be cash generative for the year and the Board
expects cash balances to be at least GBP4.6m at the end of the year
(31 Dec 2020: GBP0.47m) .
The current expectations, available to the market ahead of this
trading update, can be viewed here:
http://www.sealadvisors.com/MHC_Oberon_SEAL_12102021_final.pdf
This new guidance from the Company assumes that there will be no
material changes to COVID restrictions imposed by the UK Government
over the next two weeks, which might significantly impact the
ability for passengers to travel in or out of the UK. The Company
will provide a further update on year end trading in mid-January
2022.
Penny McCormick, Chief Executive Officer of MyHealthChecked Plc,
said: "The commercial progress that we've made during the last year
has been extraordinary and a real credit to the hard work of our
growing team. As well as having a significant positive impact on
our financial performance in 2021, this has provided us with a
strong base from which to develop our extended product pipeline
ready for commercialisation next year.
"We have established strong commercial partnerships with both of
the UK's top pharmacy retailers and executed on a business
development strategy across direct to consumer, retail and B2B
channels. Next year we look forward to launching an initial
portfolio of home wellness tests alongside our enhanced digital
platform, providing indications around weight management, vitamin
deficiency, food intolerances, heart health and blood glucose and
expect these tests and accompanying digital outputs to be the first
in a new portfolio of long-term growth drivers for our
business."
For further information contact:
MyHealthChecked plc www.myhealthchecked.com
P enny McCormick , Chief Executive via Walbrook PR
Officer
Gareth Davies, Chief Financial and
Operations Officer
SPARK Advisory Partners Limited (NOMAD) Tel: +44 (0)20 3368 3550
Neil Baldwin
Oberon Capital Ltd (Broker) Tel: +44 (0)203 179 5344
Mike Seabrook mikeseabrook@oberoninvestments.com
Walbrook PR Ltd (Media & Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
IR)
Paul McManus / Alice Woodings Mob: +44(0)7980 541 893 / +44 (0)7407
804 654
About MyHealthChecked PLC ( www.myhealthcheckedplc.com )
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted
pioneering UK healthcare company focused on a range of at-home
healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home DNA
and RNA tests, now in development following the acquisition of The
Genome Store in November 2020. The tests will be made available
online, and would be viable for over the counter purchase.
The MyHealthChecked portfolio has been identified as part of a
change in mindset as customers become more familiar with the
concept of accessible healthcare in the growing at home testing kit
market with a focus on accessibility at the right price, led by
UK-based experts.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTFFLFUEEFSELE
(END) Dow Jones Newswires
December 13, 2021 02:00 ET (07:00 GMT)
MyHealthChecked (AQSE:MHC.GB)
Historical Stock Chart
From Dec 2024 to Jan 2025
MyHealthChecked (AQSE:MHC.GB)
Historical Stock Chart
From Jan 2024 to Jan 2025